MEP33008A - Bicyclic imino acid derivatives used as inhibitors of matrixmetalloproteinases - Google Patents
Bicyclic imino acid derivatives used as inhibitors of matrixmetalloproteinasesInfo
- Publication number
- MEP33008A MEP33008A MEP-330/08A MEP33008A MEP33008A ME P33008 A MEP33008 A ME P33008A ME P33008 A MEP33008 A ME P33008A ME P33008 A MEP33008 A ME P33008A
- Authority
- ME
- Montenegro
- Prior art keywords
- diseases
- joint
- matrixmetalloproteinases
- inhibitors
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Abstract
Jedinjenja formule I su pogodna za proizvodnju ljekova za profi laksu i liječenje svih onih oboljenja, u čijem toku sudjeluje pojačana akti vnost matrix-metaloproteinaza. Tu spadaju oboljenja kao što su degenerati vna oboljenja zglobova kao npr. Osteoartroze, spondiloze, atrofi ja hrskavice poslije traume zgloba ili dužeg mirovanja zgloba poslije povrede meniskusa ili povrede čašice u koljenu ili prekida veze (ligamenta) ili oboljenja vezivanog tkiva kao što su kolagenaze, periodontalna oboljenja, smetnje pri zacjeljenju rana i hronična oboljenja sistema za kretanje kao što su zapaljenski, imunološki ili metabolički uslovljenja akutna i hronična zapaljenja zglobova, artropati je, mialgije i oštećenja metabolizma kosti ju ili ulceracije, ateroskleroze i stenoze ili za bolesti zapaljenja ili bolesti raka, nastupanja metastaze, anoreksije ili septi čkih šokova.The compounds of the formula I are suitable for the production of medicaments for the prophylaxis and the treatment of all those diseases in the course of which the enhanced activity of matrix metalloproteinases participates. These include diseases such as degenerative joint diseases such as Osteoarthritis, spondylosis, cartilage atrophy after joint trauma or prolonged joint rest after meniscus injury or cup injury in the knee or rupture of ligaments or connective tissue diseases such as collagenases, periodontal diseases, disorders in wound healing and chronic healing such as inflammatory, immunological or metabolic conditions of acute and chronic inflammation of the joints, arthropathy, myalgia and damage to bone metabolism or ulceration, atherosclerosis and stenosis or for inflammatory diseases or cancer, metastasis, anorexia or septic shocks.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344936A DE10344936A1 (en) | 2003-09-27 | 2003-09-27 | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases |
| PCT/EP2004/010248 WO2005030728A1 (en) | 2003-09-27 | 2004-09-14 | Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP33008A true MEP33008A (en) | 2010-10-10 |
Family
ID=34353126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-330/08A MEP33008A (en) | 2003-09-27 | 2004-09-14 | Bicyclic imino acid derivatives used as inhibitors of matrixmetalloproteinases |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1670766B1 (en) |
| JP (1) | JP4861179B2 (en) |
| KR (1) | KR20060086367A (en) |
| CN (1) | CN1856478B (en) |
| AR (1) | AR046165A1 (en) |
| AT (1) | ATE550327T1 (en) |
| AU (1) | AU2004275937A1 (en) |
| BR (1) | BRPI0414594A (en) |
| CA (1) | CA2539731A1 (en) |
| DE (1) | DE10344936A1 (en) |
| IL (1) | IL174040A0 (en) |
| MA (1) | MA28075A1 (en) |
| ME (1) | MEP33008A (en) |
| MX (1) | MXPA06002927A (en) |
| MY (1) | MY139830A (en) |
| NO (1) | NO20061837L (en) |
| NZ (1) | NZ546158A (en) |
| PE (1) | PE20050432A1 (en) |
| RS (1) | RS20060194A (en) |
| RU (1) | RU2335494C2 (en) |
| TW (1) | TW200520755A (en) |
| UY (1) | UY28539A1 (en) |
| WO (1) | WO2005030728A1 (en) |
| ZA (1) | ZA200601501B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004031850A1 (en) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicaments |
| DE102004031620A1 (en) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-trifluoromethoxyphenoxybenzene-4'-sulphonic acids, process for their preparation and use in medicaments |
| DE102005002500A1 (en) * | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuran derivatives as inhibitors of matrix metalloproteinases |
| DE102005015040A1 (en) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicament |
| ES2658964T3 (en) | 2007-08-03 | 2018-03-13 | Nucitec S.A. De C.V. | Compositions and methods for the treatment and prevention of osteoarthritis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201303B (en) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| FR2701480B1 (en) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Compounds with a sulfamoyl and amidino group, process for their preparation and pharmaceutical compositions containing them. |
| ATE213232T1 (en) * | 1995-11-13 | 2002-02-15 | Hoechst Ag | CYCLIC AND HETEROCYCLIC N-SUBSTITUTED ALPHA-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS |
| KR20000035917A (en) * | 1996-08-28 | 2000-06-26 | 데이비드 엠 모이어 | 1,4-heterocyclic metalloprotease inhibitors |
| CA2278694C (en) * | 1997-01-23 | 2006-09-26 | F. Hoffmann-La Roche Ag | Sulfamide-metalloprotease inhibitors |
| DE10300015A1 (en) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Imino acid derivatives as inhibitors of matrix metal proteinases |
| DE102004031620A1 (en) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-trifluoromethoxyphenoxybenzene-4'-sulphonic acids, process for their preparation and use in medicaments |
-
2003
- 2003-09-27 DE DE10344936A patent/DE10344936A1/en not_active Withdrawn
-
2004
- 2004-09-14 WO PCT/EP2004/010248 patent/WO2005030728A1/en active Application Filing
- 2004-09-14 JP JP2006527308A patent/JP4861179B2/en not_active Expired - Fee Related
- 2004-09-14 CN CN2004800279029A patent/CN1856478B/en not_active Expired - Fee Related
- 2004-09-14 EP EP04786944A patent/EP1670766B1/en active Active
- 2004-09-14 KR KR1020067005981A patent/KR20060086367A/en not_active Application Discontinuation
- 2004-09-14 RU RU2006114352/04A patent/RU2335494C2/en not_active IP Right Cessation
- 2004-09-14 ME MEP-330/08A patent/MEP33008A/en unknown
- 2004-09-14 AU AU2004275937A patent/AU2004275937A1/en not_active Abandoned
- 2004-09-14 NZ NZ546158A patent/NZ546158A/en unknown
- 2004-09-14 AT AT04786944T patent/ATE550327T1/en active
- 2004-09-14 CA CA002539731A patent/CA2539731A1/en not_active Abandoned
- 2004-09-14 RS YUP-2006/0194A patent/RS20060194A/en unknown
- 2004-09-14 MX MXPA06002927A patent/MXPA06002927A/en active IP Right Grant
- 2004-09-14 BR BRPI0414594-1A patent/BRPI0414594A/en not_active IP Right Cessation
- 2004-09-21 PE PE2004000918A patent/PE20050432A1/en not_active Application Discontinuation
- 2004-09-23 TW TW093128791A patent/TW200520755A/en unknown
- 2004-09-23 AR ARP040103437A patent/AR046165A1/en not_active Application Discontinuation
- 2004-09-25 MY MYPI20043935A patent/MY139830A/en unknown
- 2004-09-27 UY UY28539A patent/UY28539A1/en unknown
-
2006
- 2006-02-21 ZA ZA200601501A patent/ZA200601501B/en unknown
- 2006-03-01 IL IL174040A patent/IL174040A0/en unknown
- 2006-03-27 MA MA28892A patent/MA28075A1/en unknown
- 2006-04-26 NO NO20061837A patent/NO20061837L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1856478B (en) | 2010-05-26 |
| PE20050432A1 (en) | 2005-07-21 |
| UY28539A1 (en) | 2005-04-29 |
| WO2005030728A1 (en) | 2005-04-07 |
| RU2335494C2 (en) | 2008-10-10 |
| MXPA06002927A (en) | 2006-06-14 |
| AU2004275937A1 (en) | 2005-04-07 |
| ZA200601501B (en) | 2007-04-25 |
| DE10344936A1 (en) | 2005-04-21 |
| NZ546158A (en) | 2008-11-28 |
| EP1670766A1 (en) | 2006-06-21 |
| ATE550327T1 (en) | 2012-04-15 |
| IL174040A0 (en) | 2006-08-01 |
| CN1856478A (en) | 2006-11-01 |
| JP2007506690A (en) | 2007-03-22 |
| NO20061837L (en) | 2006-06-01 |
| BRPI0414594A (en) | 2006-11-07 |
| EP1670766B1 (en) | 2012-03-21 |
| RU2006114352A (en) | 2006-08-27 |
| TW200520755A (en) | 2005-07-01 |
| MY139830A (en) | 2009-10-30 |
| RS20060194A (en) | 2008-08-07 |
| CA2539731A1 (en) | 2005-04-07 |
| JP4861179B2 (en) | 2012-01-25 |
| MA28075A1 (en) | 2006-08-01 |
| AR046165A1 (en) | 2005-11-30 |
| KR20060086367A (en) | 2006-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050532A2 (en) | Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof | |
| HRP20050531B1 (en) | Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof | |
| EA201290389A8 (en) | APPLICATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES TO TREAT LIVER DISEASES | |
| AR002267A1 (en) | IMIDAZOLE COMPOUNDS USEFUL FOR THE TREATMENT OF PATHOLOGIES MEDIATED BY CYTOKINES; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; PROCESS TO PREPARE SUCH COMPOUNDS; USE OF THE SAME TO PREPARE SUCH COMPOSITIONS; INTERMEDIATE COMPOUNDS AND PROCESSES FOR ITS PREPARATION. | |
| MA33909B1 (en) | Pyrolidine is adherent as syk inhibitors | |
| MY147449A (en) | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | |
| ES2192192T3 (en) | CATECOL DIETS AS SELECTIVE PDE INHIBITORS IV. | |
| BRPI0607583A2 (en) | pyridin-2-carboxamide derivatives as mglur5 antagonists, method for their preparation, medicament containing same as well as use related to said compounds | |
| EA200400595A1 (en) | BENZIMIDAZOLY, USED AS PROTEKINKINASE INHIBITORS | |
| ECSP066383A (en) | DERIVATIVES OF 5-PHENYL-4-METHYL-TIAZOL-2-IL-AMINA AS INHIBITORS OF KINASA ENZYMES PHOSFATIDILINOSITOL 3 (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY ROUTES | |
| NO20062692L (en) | Heterocyclic MEK inhibitors and methods for their use | |
| IS8175A (en) | Piperazine derivatives and methods of their use | |
| ME00768B (en) | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors | |
| ITMI20031311A1 (en) | FORMULATIONS FOR THE TREATMENT OF ARTHROSIC DISORDERS. | |
| EA200700902A1 (en) | 3-ARYLAMINOPYRIDINE DERIVATIVES | |
| BR0314314A (en) | 4-Pyrrolidine-phenyl-benzyl ether derivatives | |
| CL2004000848A1 (en) | COMPOUNDS DERIVED FROM FENACIL-2-HIDROXI-3-DIAMINOALCANS, INHIBITORS OF THE ENZYME BETASECRETASA, USEFUL TO PREPARE A MEDICINAL PRODUCT TO TREAT ALZHEIMER, DOWN SYNDROME, HEREDITAR CEREBRAL HERIDAL AND OEREDOS | |
| BRPI0507041A (en) | sulfonamide-derived compounds for the treatment of diseases their uses, process for the preparation of compounds and combination of compounds | |
| BRPI0709581A8 (en) | bicycloetheroyl compounds as px27 modulators and their use | |
| UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
| BRPI0411936A (en) | compound, process for its preparation, pharmaceutical composition comprising the same, use of a compound, methods for the treatment and prophylaxis of central nervous system disorders, eating disorders and obesity | |
| ATE512147T1 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| BRPI0713443A2 (en) | PIPERAZINILY DERIVATIVES USEFUL IN THE TREATMENT OF MEDICAL DISEASES BY GPR38 RECEIVER, USE AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUNDS AND PREPARATION PROCESSES | |
| EA200200520A1 (en) | Derivatives of Heterocycloalkylsulfonylpyrazole as an Anti-Inflammatory / Analogical Agents | |
| BR0306643A (en) | Novel hydroxy alkyl / aryl or keto tiepine compounds as inhibitors of apical bile acid sodium co-dependent transport |